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Preamble
These recommendations provide a data-supported
approach to establishing guidelines. They are based on
the following: (1) a formal review and analysis of the
recently published world literature on the topic; (2)
the American College of Physicians Manual for Assess-
ing Health Practices and Designing Practice Guidelines
1;
(3) guideline policies including the AASLD Policy on
the Development and Use of Practice Guidelines and the
American Gastroenterological Association’s Policy State-
ment on the Use of Medical Practice Guidelines
2; and
(4) the experience of the authors in regard to
hemochromatosis.
To more fully characterize the available evidence
supporting the recommendations, the AASLD Practice
Guidelines Committee has adopted the classiﬁcation
used by the Grading of Recommendation Assessment,
Development, and Evaluation (GRADE) workgroup
with minor modiﬁcations (Table 1).
3 The strength of
recommendations in the GRADE system are classiﬁed
as strong (class 1) or weak (class 2). The quality of
evidence supporting strong or weak recommendations
is designated by one of three levels: high (level A),
moderate (level B), or low-quality (level C).
Intended for use by physicians, these recommenda-
tions suggest preferred approaches to the diagnostic,
therapeutic, and preventive aspects of care. They are
intended to be ﬂexible in contrast to standards of care,
which are inﬂexible policies to be followed in every
case. Speciﬁc recommendations are based on relevant
published information.
3,4
Introduction
Hereditary hemochromatosis (HH) remains the
most common, identiﬁed, genetic disorder in Cauca-
sians. Although its geographic distribution is world-
wide, it is seen most commonly in populations of
northern European origin, particularly Nordic or
Celtic ancestry, in which it occurs with a prevalence of
approximately 1 per 220-250 individuals.
5,6 The
pathophysiologic predisposition to increased, inappro-
priate absorption of dietary iron may lead to the devel-
opment of life-threatening complications of cirrhosis,
hepatocellular carcinoma (HCC), diabetes, and heart
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328disease. The principal HFE gene defect was ﬁrst
described in 1996, and is a G-to-A missense mutation
leading to the substitution of tyrosine for cysteine at
amino acid position 282 of the protein product
(C282Y).
7 C282Y homozygotes account for 80%-85%
of typical patients with HH.
8 There are two other regu-
larly identiﬁed mutations, one in which aspartate is sub-
stituted for histidine at amino acid position 63 (H63D),
and the other in which cysteine is substituted for serine
at amino acid position 65 (S65C). These are generally
not associated with iron loading unless seen with C282Y
as a compound heterozygote, C282Y/H63D or C282Y/
S65C (Fig. 1). Over the last 10 years, mutations of other
genes coding for iron regulatory proteins have been
implicated in inherited iron overload syndromes (e.g.,
hepcidin, hemojuvelin, transferrin receptor 2, and ferro-
portin). These are thought to account for most of the
non-HFE forms of HH.
9
With the advent of genetic testing in the late 1990s,
HFE-related HH is now frequently identiﬁed in
asymptomatic probands and in presymptomatic rela-
tives of patients who are known to have the disease.
Accordingly, a genetic diagnosis can be applied to indi-
viduals who have not yet developed any phenotypic
expression. Therefore, these individuals have a ‘‘genetic
susceptibility’’ to developing iron overload but may
never do so, for reasons that are still to be deter-
mined.
6,10-12 This observation has changed the way we
think about hemochromatosis. Twenty years ago, it
was considered that all individuals who were geneti-
cally susceptible would ultimately have evidence of
phenotypic expression. Now, it is clear that phenotypic
expression only occurs in approximately 70% of
C282Y homozygotes, and fewer than 10% of C282Y
homozygotes will develop severe iron overload accom-
panied by organ damage and clinical manifestations of
hemochromatosis.
10,12 This acknowledgment has led
to a recognition of the different stages and progression
of hemochromatosis identiﬁed at a consensus confer-
ence of the European Association for the Study of
Liver Diseases in 2000.
13 These stages are deﬁned as
follows:
• Stage 1 refers to those patients with the genetic dis-
order with no increase in iron stores who have ‘‘genetic
susceptibility.’’
• Stage 2 refers to those patients with the genetic dis-
order who have phenotypic evidence of iron overload
but who are without tissue or organ damage.
• Stage 3 refers to those individuals who have the
genetic disorder with iron overload and have iron depo-
sition to the degree that tissue and organ damage occurs.
This organizational schema is important to allow
clinicians to categorize patients who have positive
genetic test results.
Causes of Iron Overload
The current classiﬁcation of iron overload syn-
dromes divides patients into three groups (Table 2):
(1) those who have inherited causes of iron overload,
(2) those who have various causes of secondary iron
overload, and (3) a small miscellaneous group.
Approximately 85%-90% of patients who have inher-
ited forms of iron overload are homozygous for the
C282Y mutation in HFE, with a small minority who
are compound heterozygotes, meaning that one allele
has the C282Y mutation and one allele has the H63D
or the S65C mutation. The remaining 10%-15% of
patients who have inherited forms of iron overload
most likely have mutations in one of the other
Table 1. Grading of Recommendations, Assessment,
Development, and Evaluation (GRADE)
Strength of
Recommendation Criteria
Strong (1) Factors inﬂuencing the strength of the recommendation
included the quality of the evidence, presumed
patient-important outcomes, and cost
Weak (2) Variability in preferences and values, or more uncertainty.
Recommendation is made with less certainty, or higher
cost or resource consumption
Quality of
Evidence
Criteria
High (A) Further research is unlikely to change conﬁdence in the
estimate of the clinical effect
Moderate (B) Further research may change conﬁdence in the estimate
of the clinical effect
Low (C) Further research is very likely to impact conﬁdence on
the estimate of clinical effect
Fig. 1. Schematic representation of the protein product of HFE.
Most of the protein is extracellular. There is a short cytoplasmic tail
and three extracellular alpha loops. The three principal mutations are
identiﬁed.
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9
Causes of secondary iron overload are divided between
those causes related to iron loading anemias, those
related to chronic liver disease, transfusional iron over-
load, and miscellaneous causes. Oral iron ingestion
does not lead to iron overload except in genetically
predisposed individuals or those who have ineffective
erythropoiesis.
Other inherited forms of iron overload, classiﬁed as
non–HFE-related HH, are juvenile hemochromatosis
and iron overload resulting from mutations in the
genes for transferrin receptor 2 (TfR2), or ferroportin
(SLC40A1).
9 Juvenile HH is characterized by rapid
iron accumulation. Mutations in two different genes
(hemojuvelin and hepcidin) have been shown to cause
two forms of juvenile HH.
14 The more common
mutation occurs in the hemojuvelin (HJV) gene on
chromosome 1q.
15 Mutations in the hepcidin gene
(HAMP) also produce a form of juvenile HH, but this
is much less common.
14 Hepcidin is a 25–amino acid
peptide produced in the liver that down-regulates iron
absorption. Mutations in the TfR2 gene produce an
autosomal recessive form of HH that is clinically simi-
lar to HFE-related HH.
16 These mutations may cause
abnormal iron sensing by hepatocytes, which is the
predominant site of TfR2 expression. The distribution
of excess iron is similar to that in HFE-related HH,
namely, primarily in hepatic parenchymal cells.
16 A
rare autosomal dominant form of HH results from
two categories of mutations in the gene for the iron
transporter protein, ferroportin. ‘‘Loss-of-function’’
mutations decrease the cell surface localization of ferro-
portin, thereby reducing its ability to export iron.
17,18
The result is iron deposition primarily in macrophages,
and this disorder is called ‘‘ferroportin disease’’. The
second category of mutation includes ‘‘gain-of-func-
tion’’ ferroportin mutations that abolish hepcidin-
induced ferroportin internalization and degradation
18;
distribution of iron is similar to HFE-related HH,
concentrating predominantly in parenchymal cells.
African iron overload occurs primarily in sub-
Saharan Africa and is now considered to be the result
of a non–HFE-related genetic abnormality that can be
exacerbated by dietary iron loading.
19 Some individu-
als with African iron overload drink an iron-rich fer-
mented beverage, but iron overload can also occur in
people who do not drink this beverage.
19
Causes of Secondary Iron Overload and Miscella-
neous Disorders. Individuals who absorb excessive
amounts of iron as a result of an underlying defect
other than any of the previously mentioned inherited
disorders have secondary iron overload.
20 The most
common causes of secondary iron overload are individ-
uals with ineffective erythropoiesis, parenteral iron
overload, and liver disease. Individuals who receive
blood transfusions and who have transfusional or par-
enteral iron overload should be distinguished from
those who have other causes of secondary iron over-
load. Parenteral iron overload is always iatrogenic, in
that blood or iron (given parenterally) must be ordered
by a health care provider prior to its administration.
Many individuals with ineffective erythropoiesis who
have decreased utilization of iron by the bone marrow
also have transfusional iron overload because of a
requirement for transfusions.
20
Recently, it has been found that neonatal hemochro-
matosis is actually a form of congenital alloimmune
hepatitis with subsequent iron deposition.
21 In these
cases, immune-mediated liver injury in the fetus is
associated with the development of iron overload.
Administration of intravenous immunoglobulin during
pregnancy slows or prevents the development of this
condition.
22 Other rare miscellaneous disorders include
congenital atransferrinemia and aceruloplasminemia.
Table 2. Classiﬁcation of Iron Overload Syndromes
Hereditary Hemochromatosis
HFE-related
C282Y/C282Y
C282Y/H63D
Other HFE mutations
Non–HFE-related
Hemojuvelin (HJV)
Transferrin receptor-2 (TfR2)
Ferroportin (SLC40A1)
Hepcidin (HAMP)
African iron overload
Secondary Iron Overload
Iron-loading anemias
Thalassemia major
Sideroblastic
Chronic hemolytic anemia
Aplastic anemia
Pyruvate kinase deﬁciency
Pyridoxine-responsive anemia
Parenteral iron overload
Red blood cell transfusions
Iron–dextran injections
Long-term hemodialysis
Chronic liver disease
Porphyria cutanea tarda
Hepatitis C
Hepatitis B
Alcoholic liver disease
Nonalcoholic fatty liver disease
Following portocaval shunt
Dysmetabolic iron overload syndrome
Miscellaneous
Neonatal iron overload
Aceruloplasminemia
Congenital atransferrinemia
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There are four main categories of pathophysiological
mechanisms of HH that should be mentioned: (1) the
increased absorption of dietary iron in the upper intes-
tine, (2) decreased expression of the iron-regulatory
hormone hepcidin, (3) the altered function of HFE
protein, and (4) tissue injury and ﬁbrogenesis induced
by iron.
Intestinal Iron Absorption. The ﬁrst link between
HFE protein and cellular iron metabolism resulted
from the observation that the HFE protein along with
b2-microglobulin forms a complex with transferrin re-
ceptor-1 (TfR1).
23 This physical association was
observed in cultured cells and in duodenal crypt enter-
ocytes, which have been considered to be the predomi-
nant site of regulation of dietary iron absorption. The
observation that HFE protein and TfR1 were physi-
cally associated led to a number of investigations of
the effect of HFE protein on TfR1-mediated iron
uptake and cellular iron stores.
24 The ‘‘crypt cell hy-
pothesis’’ of iron regulation is now regarded as much
less important since the discovery of the central role of
hepcidin in the regulation of iron metabolism.
Hepcidin. Hepcidin is a 25–amino acid peptide
that inﬂuences systemic iron status.
25 It is considered
to be the principal iron-regulatory hormone. Alteration
in the regulation of hepcidin plays an important role
in the pathogenesis of hemochromatosis. Hepcidin is
expressed predominantly in hepatocytes and is secreted
into the circulation. It binds to ferroportin, which is
found in macrophages and on the basolateral surface
of enteroctyes. When hepcidin binds to ferroportin,
the ferroportin is internalized and degraded and iron
export by these two cell types (macrophages and enter-
ocytes) is inhibited.
26 Hepcidin expression induced by
excess iron or inﬂammation results in decreased intesti-
nal iron absorption and diminished iron release from
macrophages.
25
In contrast, hepcidin expression is decreased by iron
deﬁciency, ineffective erythropoiesis, and hypoxia, with
resulting increases in iron absorption from the intes-
tine and release of iron from macrophages.
25 Muta-
tions in human disease or murine knockouts of the
genes for HFE, hemojuvelin, hepcidin, or TfR2
decrease hepcidin expression with a resulting increase
in intestinal iron absorption via up-regulation of ferro-
portin levels in enterocytes.
25
Studies have revealed that iron-induced regulation
of hepcidin expression involves a bone morphogenetic
protein 6 (BMP6)-dependent signaling pathway.
27
BMP6 binds to a speciﬁc receptor on hepatocytes trig-
gering SMAD protein–dependent activation of hepci-
din expression. Selective inhibition of BMP6 signaling
abrogates iron-induced up-regulation of hepcidin.
27
Hemojuvelin is a BMP6 coreceptor, and it facilitates
the binding of BMP6 to its receptor; knockout of the
HJV gene markedly decreases BMP6 signaling in hep-
cidin expression and causes iron overload.
28
HFE Protein. The extracellular domain of HFE
protein consists of three loops with intramolecular di-
sulﬁde bonds within the second and third loops
7 (Fig.
1). The structure of the HFE protein is similar to that
of other major histocompatibility complex class-1 pro-
teins, but evidence indicates that HFE protein does
not participate in antigen presentation.
29 HFE protein
is physically associated with b2-microglobulin, similar
to other major histocompatibility complex class-1 mol-
ecules. The major mechanisms by which HFE inﬂuen-
ces iron-dependent regulation of hepcidin remain
unclear. HFE can bind to both TfR2 and to the classic
transferrin receptor TfR1.
23,30 In addition, both HFE
and TfR2 may interact with HJV, suggesting that a
complex of HFE and TfR2 may play a regulatory role
in BMP6 signaling.
28 One proposed explanation sug-
gests that the complex of TfR1 and HFE acts as an
iron sensor at the cell membrane of the hepatocyte.
30
As transferrin saturation (TS) increases, diferric trans-
ferrin displaces HFE from TfR1, thereby making HFE
available to bind to TfR2. It is postulated that the
complex of HFE and TfR2 then inﬂuences hepcidin
expression. Figure 2 summarizes these interactions.
31
Liver Damage. Another major pathophysiologic
mechanism in HH relates to the liver damage that
results from iron overload.
32 In patients with advanced
HH, hepatic ﬁbrosis and cirrhosis are the principal
pathological ﬁndings. Numerous studies using experi-
mental hepatic iron overload have identiﬁed iron-de-
pendent oxidative damage and associated impairment
of membrane-dependent functions of mitochondria,
microsomes, and lysosomes.
33,34 One hypothesis is
that iron-induced lipid peroxidation occurs in hepato-
cytes and causes hepatocellular injury or death. Kupffer
cells become activated byproducts released from
injured iron-loaded hepatocytes and produce proﬁbro-
genic cytokines, which in turn stimulate hepatic stel-
late cells to synthesize increased amounts of collagen,
thereby leading to pathologic ﬁbrosis.
32,35
Clinical Features
Hemochromatosis is increasingly being recognized
by clinicians. Nonetheless, it is still underdiagnosed,
because it is often considered a rare disorder that is
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lished disease consisting of cirrhosis, diabetes, and skin
pigmentation (so-called ‘‘bronze diabetes’’). Genetic
susceptibility (C282Y homozygosity) for hemochroma-
tosis is seen in approximately one in 250 Caucasians;
however, fully expressed disease with end-organ mani-
festations is seen in fewer than 10% of these individu-
als.
10,12 The reasons for the lack of phenotypic expres-
sion are unknown. It may involve interactions with
gene products of other proteins involved in iron ho-
meostasis (with or without mutation). This can explain
the discrepancy between the high incidence of C282Y
homozygosity in Caucasians (one in 250) versus how
infrequently the full clinical manifestations of the dis-
ease are seen (approximately one in 2500). The hetero-
zygote genotype (C282Y/wild type) is found in
approximately one in 10 individuals and may be asso-
ciated with elevated serum iron markers, but without
associated tissue iron overload or damage.
Clinical manifestations in patients reported in series
from the 1950s to the 1980s showed that most
reported patients had classic symptoms and ﬁndings of
advanced hemochromatosis (Table 3).
36-38 By the
1990s, HH was increasingly being identiﬁed in patients
who had abnormal iron studies on routine chemistry
panels or by patients having been identiﬁed by family
screening.
39,40 When patients with HH were identiﬁed
in this way, approximately 75% of them did not have
symptoms and did not exhibit any of the end-stage
manifestations of the disease. Currently, in large popu-
lation screening studies, only approximately 70% of
C282Y homozygotes are found to have an elevated fer-
ritin level indicative of increased iron stores (Table 4),
and only a small percentage of these patients have clini-
cal consequences of iron storage disease.
6,10,12,41,42
More men than women have increased ferritin levels.
Nonetheless, it is still important for clinicians to be
aware of the symptoms that patients may exhibit and
the physical ﬁndings with which they can present.
When patients present with symptoms, hemochroma-
tosis should be considered when there are complaints of
fatigue, right upper quadrant abdominal pain, arthral-
gias, (typically of the second and third metacarpopha-
langeal joints), chondrocalcinosis, impotence, decreased
libido, and symptoms of heart failure or diabetes
(Table 5). Similarly, physical ﬁndings of an enlarged
liver, particularly in the presence of cirrhosis, extrahe-
patic manifestations of chronic liver disease, testicular
atrophy, congestive heart failure, skin pigmentation,
changes of porphyria cutanea tarda (PCT), or arthritis
should raise the suspicion of hemochromatosis (Table 6).
Many of these features are indicative of disease processes
other than hemochromatosis, but the thoughtful clini-
cian will make sure that hemochromatosis has been
considered when patients who exhibit these symptoms
or signs are seen. Currently, most new patients with HH
Fig. 2. Summary of interactions between duo-
denal enterocytes, hepatocytes, and macro-
phages in iron homeostasis regulated by
hepcidin. FPN, ferroportin. (Adapted from Cama-
schella C. BMP6 orchestrates iron metabolism.
Nat Genet 2009;41:386–388. Used with permis-
sion from Nature Genetics. Copyright V C 2009,
Nature Publishing Group).
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in family studies, or by evaluation of abnormal labora-
tory studies by primary care physicians. In older series
of patients with HH, when patients were identiﬁed by
symptoms or physical ﬁndings of the disease, women
typically presented approximately 10 years later than
men, and there were approximately 10 times as many
men presenting as women. This sex difference is likely
because of menstrual blood loss and maternal iron loss
during pregnancy having a ‘‘protective’’ effect for
women. More recently, with a greater proportion of
patients identiﬁed by screening studies, the age of diag-
nosis for women and men has equalized, and the num-
bers of men and women identiﬁed are roughly equiva-
lent.
6,10 Nonetheless, the proportion of C282Y
homozygous women with deﬁnite disease manifestations
(e.g., liver disease, arthritis) is signiﬁcantly lower than
men (1% versus 25%, respectively).
10
Recommendations:
1. We recommend that patients with abnormal
iron studies should be evaluated as patients with
hemochromatosis, even in the absence of symptoms.
(A)
2. All patients with evidence of liver disease should
be evaluated for hemochromatosis. (1B)
Diagnosis
The clinical diagnosis of hemochromatosis is based
on documentation of increased iron stores, demon-
strated by elevated serum ferritin levels, which reﬂects
an increase in hepatic iron content. HH can be further
deﬁned genotypically by the familial occurrence of
iron overload associated with C282Y homozygosity or
C282Y/H63D compound heterozygosity. Serologic
iron markers (TS, ferritin) are widely available, and
the majority of patients with HH are now identiﬁed
while still asymptomatic and without evidence of he-
patic ﬁbrosis or cirrhosis. There are certain high-risk
groups that should be targeted for evaluation, such as
those with a family history of HH, those with sus-
pected organ involvement, and those with chance
detection of biochemical and/or radiological abnormal-
ities suggestive of the possibility of iron overload. It is
generally recommended that all patients with abnormal
liver function have iron studies done at some point in
their evaluation. The algorithm outlined in Fig. 3 can
provide some further direction regarding testing and is
modiﬁed from the version used in the previous
AASLD guidelines.
42
Table 3. Principal Clinical Features in Hereditary Hemochromatosis
Features
Study (Year)
Milder et al.
37 (1980) Edwards et al.
36 (1980) Niederau et al.
38 (1985) Adams et al.
39 (1991) Bacon and Sadiq
40 (1997)
Number of subjects 34† 35* 163* 37‡ 40
Symptoms (%)
Weakness, lethargy 73 20 83 19 25
Abdominal pain 50 23 58 3 0
Arthralgias 47 57 43 40 13
Loss of libido, impotence 56 29 38 32 12
Cardiac failure symptoms 35 0 15 3 0
Physical and Diagnostic Findings (%)
Cirrhosis (biopsy) 94 57 69 3 13
Hepatomegaly 76 54 83 3 13
Splenomegaly 38 40 13 – –
Loss of body hair 32 6 20 – –
Gynecomastia 12 – 8 – –
Testicular atrophy 50 14 – – –
Skin pigmentation 82 43 75 9 5
Clinical diabetes 53 6 55 11 –
*Patient selection occurred by both clinical features and family screening.
†Only symptomatic index cases were studied.
‡Discovered by family studies.
Table 4. Prevalence of C282Y Homozygotes Without Iron
Overload in Large Screening Studies
Population Sample Country n
Prevalence of
Homozygotes
C282Y Homozygotes
with Normal
Ferritin Level (%)
Primary care (
12) USA 41,038 1 in 270 35
General public (
11) Norway 65,238 1 in 220 13
Primary care (
6) North America 99,711 1 in 333 31
General public (
10) Australia 29,676 1 in 146 32
Total 235,663 1 in 240 30
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markers of iron stores, namely TS or unsaturated iron-
binding capacity and serum ferritin (Table 7). TS is
calculated from the ratio of serum iron to total iron-
binding capacity. In some laboratories, the total iron-
binding capacity is calculated from the sum of the
serum iron and the unsaturated iron-binding capacity,
whereas in others, it is calculated indirectly from the
transferrin concentration in the serum. A recent study,
using fasting samples, has shown no improvement in
sensitivity or speciﬁcity in the detection of C282Y
homozygotes.
43 Accordingly, this prior recommenda-
tion is no longer absolutely necessary, although it is
advisable to conﬁrm an elevated TS with a second
determination and it is not unreasonable in our opin-
ion to do this on a fasting specimen. Over the years,
different studies have used a variety of cutoff values
for TS to identify patients eligible for further testing.
Although a cutoff TS value of 45% is often chosen for
its high sensitivity for detecting C282Y homozygotes,
it has a lower speciﬁcity and positive predictive value
compared to higher cutoff values. Thus, using a cutoff
TS of 45% will also identify persons with minor sec-
ondary iron overload as well as some C282Y/wild-type
heterozygotes, and these cases will require further
evaluation.
44
Serum ferritin has less biological variability than TS,
but it has a signiﬁcant false positive rate because of ele-
vations related to inﬂammation. Ferritin can be ele-
vated in the absence of increased iron stores in patients
with necroinﬂammatory liver disease (alcoholic liver
disease [ALD], chronic hepatitis B and C, nonalcoholic
fatty liver disease [NAFLD]), in lymphomas, and in
patients with other nonhepatic chronic inﬂammatory
conditions. In fact, in the general population, iron
overload is not the most common cause of an elevated
ferritin level. Nonetheless, in the absence of other
inﬂammatory processes, several studies of families with
HH have demonstrated that the serum ferritin concen-
tration provides a valuable correlation with the degree
of body iron stores. In most circumstances, serum ferri-
tin provides additional conﬁrmation of the signiﬁcance
of an elevated TS in C282Y homozygotes. In a study
of individuals <35 years of age, serum ferritin in the
normal range in combination with a TS < 45% had a
negative predictive value of 97% for excluding iron
overload.
45 In a large study correlating phenotypic and
genotypic markers in a primary care population in
California, a serum ferritin >250 lg/L in men and
>200 lg/L in women was positive in 77% and 56%,
respectively, of C282Y homozygotes.
12 In the HEIRS
(HEmochromatosis and IRon Overload Screening)
study that screened 99,711 North American partici-
pants, serum ferritin levels were elevated (>300 lg/L
in men, >200 lg/L in women) in 57% of female and
88% of male C282Y homozygotes.
6 It is recognized
that a variety of disease conditions unrelated to iron
overload may cause a nonspeciﬁc rise in serum ferritin,
and in the absence of an elevated TS, this rise may be
nonspeciﬁc. Conversely, iron overload may be present
in a patient with an elevated ferritin and a normal TS,
particularly in non–HFE-related iron overload or in a
C282Y/H63D compound heterozygote.
46
Serum ferritin levels have an additional value as a
predictor of advanced ﬁbrosis and cirrhosis in con-
ﬁrmed HH. Several studies have demonstrated that a
Table 5. Symptoms in Patients with HH
Asymptomatic
Abnormal serum iron studies on routine screening chemistry panel
Evaluation of abnormal liver tests
Identiﬁed by family screening
Nonspeciﬁc, systemic symptoms
Weakness
Fatigue
Lethargy
Apathy
Weight loss
Speciﬁc, organ-related symptoms
Abdominal pain (hepatomegaly)
Arthralgias (arthritis)
Diabetes (pancreas)
Amenorrhea (cirrhosis)
Loss of libido, impotence (pituitary, cirrhosis)
Congestive heart failure (heart)
Arrhythmias (heart)
Table 6. Physical Findings in Patients with HH
Asymptomatic
No physical ﬁndings
Hepatomegaly
Symptomatic
Liver
Hepatomegaly
Cutaneous stigmata of chronic liver disease
Splenomegaly
Liver failure: ascites, encephalopathy, and associated features
Joints
Arthritis
Joint swelling
Chondrocalcinosis
Heart
Dilated cardiomyopathy
Congestive heart failure
Skin
Increased pigmentation
Porphyria cutanea tarda
Endocrine
Testicular atrophy
Hypogonadism
Hypothyroidism
334 BACON ET AL. HEPATOLOGY, July 2011level of serum ferritin <1000 lg/L is an accurate pre-
dictor for the absence of cirrhosis, independent of the
duration of the disease.
47-49 A serum ferritin level
>1000 lg/L with an elevated aminotransferase level
(alanine aminotransferase [ALT] or aspartate amino-
transferase [AST]) and a platelet count <200   10
9/L
predicted the presence of cirrhosis in 80% of C282Y
homozygotes.
50
Recommendations:
3. In a patient with suggestive symptoms, physical
ﬁndings, or family history, a combination of TS and
ferritin should be obtained rather than relying on a
single test. (1B) If either is abnormal (TS   45% or
ferritin above the upper limit of normal), then HFE
mutation analysis should be performed. (1B)
4. Diagnostic strategies using serum iron markers
should target high-risk groups such as those with a
family history of HH or those with suspected organ
involvement. (1B)
Family Screening
Once a patient with HH has been identiﬁed
(proband), family screening should be recommended
for all ﬁrst-degree relatives. For ease of testing, both
genotype (HFE mutation analysis) and phenotype
(ferritin and TS) should be performed simultaneously
at a single visit. For children of an identiﬁed proband,
HFE testing of the other parent is generally recom-
mended, because if results are normal, the child is an
obligate heterozygote and need not undergo further
testing because there is no increased risk of iron load-
ing.
51 If C282Y homozygosity or compound hetero-
zygosity is found in adult relatives of a proband, and
if serum ferritin levels are increased, then therapeutic
Table 7. Laboratory Findings in Patients with HH
Normal
Patients with HH
Measurements Subjects Asymptomatic Symptomatic
Blood
Serum iron level (lg/dL) 60-80 150-280 180-300
TS (%) 20-50 45-100 80-100
Serum ferritin level (lg/L)
Men 20-200 150-1000 500-6000
Women 15-150 120-1000 500-6000
Liver
Hepatic iron concentration
lg/g dry weight 300-1500 2000-10,000 8000-30,000
lmol/g dry weight 5-27 36-179 140-550
Hepatic iron index* <1.0 >1.9 >1.9
Liver histology
Perls’ Prussian blue stain 0-1þ 2þ to 4þ 3þ,4 þ
*Hepatic iron index is calculated by dividing the hepatic iron concentration
(in lmol/g dry weight) by the age of the patient (in years). With increased
knowledge of genetic testing results in patients with iron overload, the utility of
the hepatic iron index has diminished.
Fig. 3. An algorithm can provide
some further direction regarding
testing and treatment for HH. The
algorithm is modiﬁed from the ver-
sion used in the previous AASLD
guidelines.
HEPATOLOGY, Vol. 54, No. 1, 2011 BACON ET AL. 335phlebotomy can be initiated. If ferritin level is normal
in these patients, then yearly follow-up with iron stud-
ies is indicated. When identiﬁed, C282Y heterozygotes
and H63D heterozygotes can be reassured that they
are not at risk for developing progressive or sympto-
matic iron overload. Occasional H63D homozygotes
can develop mild iron overload.
52 However, it should
be recognized that any of these genotypes can be a
cofactor for the development of liver disease when
they occur in conjunction with other liver diseases
such as PCT, hepatitis C infection, ALD, or NAFLD.
Relatives who are identiﬁed as H63D heterozygotes or
H63D homozygotes can be reassured that they are
generally not at risk of progressive iron overload,
although they may have minor abnormalities in serum
iron measurements such as TS or ferritin.
Family studies have concluded that many homozy-
gous relatives of probands demonstrate biochemical
and clinical expression of disease.
53,54 Furthermore, a
recent population study of approximately 30,000 Cau-
casian subjects aged 40-69 years identiﬁed 203 C282Y
homozygotes (108 females, 95 males). These subjects
were evaluated sequentially over a 12-year period, prior
to available knowledge of their genotype. Documented
iron overload-related disease was present in 28% of
males and 1% of females, especially when serum ferri-
tin levels were >1000 lg/L.
10
Recommendations:
5. We recommend screening (iron studies and
HFE mutation analysis) of ﬁrst-degree relatives of
patients with HFE-related HH to detect early dis-
ease and prevent complications. (1A)
Liver Biopsy
Since the advent of HFE mutation analysis, liver bi-
opsy has become less important as a clinical tool in the
diagnosis of HH. Liver biopsy should be considered
only for the purpose of determining the presence or ab-
sence of advanced ﬁbrosis or cirrhosis, which does have
prognostic value. Identiﬁcation of cirrhosis may lead to
adjustments in clinical management, such as screening
for HCC and esophageal varices (and other features of
portal hypertension).
55 The risks of liver biopsy have
been reviewed, with mild bleeding after biopsy reported
to be in the range of 1%-6%, and mortality associated
with a complication of less than 1:10,000.
56
Serum ferritin levels can help identify patients who
may beneﬁt most from having a liver biopsy. Several
studies have demonstrated that C282Y homozygotes
with a serum ferritin >1000 lg/L are at an increased
risk of cirrhosis, with a prevalence of 20%-45%.
49,50
In contrast, fewer than 2% of C282Y homozygotes
with a ferritin level <l000 lg/L at the time of diagno-
sis have cirrhosis or bridging ﬁbrosis in the absence of
another risk factor such as excessive alcohol consump-
tion, viral hepatitis, or fatty liver disease.
47-50 A recent
study of more than 670 asymptomatic C282Y homo-
zygotes described the prevalence of advanced hepatic
ﬁbrosis.
41 In this study, a liver biopsy was performed
in 350 subjects because of elevated serum ferritin levels
(using a cutoff of 500 lg/L) or abnormal serum liver
enzyme results, the presence of hepatomegaly, or a
combination of these. The majority of these biopsies
were performed for diagnosis of HH prior to the avail-
ability of HFE mutation analysis. Cirrhosis was present
in 5.6% of all males and 1.9% of all females. All sub-
jects with cirrhosis had a hepatic iron concentration
(HIC) >200 lmol/g dry weight (approximately seven
times the upper limit of normal). A serum ferritin
level >1000 lg/L had 100% sensitivity and 70% spec-
iﬁcity for identiﬁcation of cirrhosis. No subject with a
serum ferritin level <1000 lg/L had cirrhosis. These
observations must be tempered when patients with
HH also consume large amounts of alcohol. An Aus-
tralian study showed that >60% of patients with HH
who consumed >60 g alcohol/day had cirrhosis, com-
pared to <7% of those who consumed less alcohol.
57
Based on these recent studies, it can be concluded
that serum ferritin is the single most important predic-
tor of the presence of advanced hepatic ﬁbrosis in
C282Y homozygotes. Therefore, liver biopsy does not
need to be performed when ferritin is <l000 lg/L, in
the absence of excess alcohol consumption and ele-
vated serum liver enzymes.
Patients with elevated serum iron studies, but who
lack C282Y homozygosity, should be considered for
liver biopsy if they have elevated liver enzymes or
other clinical evidence of liver disease. These patients
may have non-HH liver disease such as NAFLD,
ALD, or chronic viral hepatitis.
When liver biopsy is performed, routine histopatho-
logic evaluation should include standard hematoxylin–
eosin and Masson’s trichrome stains as well as Perls’
Prussian blue stains for evaluating the degree and
cellular distribution of hepatic iron stores. In addition, a
portion of liver tissue can be obtained for measurement
of HIC. It should be recognized that HIC can also be
measured from formalin-ﬁxed, deparafﬁnized speci-
mens, but at least 4 mg dry weight of tissue should be
available for evaluation.
58 Qualitative and semiquantita-
tive methods for grading the degree of stainable hepatic
iron have been described. The Batts–Ludwig system
uses an estimation of the proportion of hepatocytes that
336 BACON ET AL. HEPATOLOGY, July 2011stain for iron, ranging from solely zone 1 (periportal) to
inclusion of zones 2 and 3 (pericentral). The grading of
iron staining ranges from grade 1 to grade 4, with grade
4 representing panlobular iron deposition.
59 A semi-
quantitative ‘‘histological hepatic iron index’’ has been
proposed based on the size and density of iron granules
in hepatocytes, sinusoidal lining cells, and portal cells.
60
This formula can be used to calculate a total iron score,
and this system has been validated and found to be use-
ful to differentiate heterozygotes from homozygotes. It
is not widely used outside the research setting.
Hepatic iron index (HII) was ﬁrst introduced in
1986 and was used frequently to support a diagnosis
of HH when the HII was >1.9, prior to the advent of
HFE mutation analysis.
61,62 HII, which measures the
rate of hepatic iron accretion, is calculated by dividing
the HIC (in lmol/g) by the patient’s age in years and
was based on the concept that homozygotes would
continue to absorb excess dietary iron throughout their
lifetime, whereas those who were heterozygotes or
those with iron overload due to associated alcohol use
would not. Several studies showed that most homozy-
gotes with iron overload had an HII > l.9 lmol/g/
year, whereas patients with other chronic diseases had
an HII < 1.9.
63,64 The availability of genetic testing
has now shown that phenotypic expression of homo-
zygosity can occur at a much lower HIC and a much
lower HII, and therefore the HII is no longer routinely
used. Recent studies show good correlation between
HIC determined on liver biopsy samples with HIC
estimated by proton transverse relaxation time deter-
mined by magnetic resonance imaging.
64
Recommendations:
6. Liver biopsy is recommended to stage the degree
of liver disease in C282Y homozygotes or compound
heterozygotes if liver enzymes (ALT, AST) are elevated
or if ferritin is >1000 lg/L. (1B)
Role of Liver Biopsy in Non–HFE-related HH
Liver biopsy may provide both diagnostic and prog-
nostic information in patients with iron overload who
are not C282Y homozygotes. Abnormal serum iron
studies are identiﬁed in approximately 50% of patients
with other liver diseases such as ALD, NAFLD, or
chronic viral hepatitis. Liver biopsy is used to evaluate
those patients both from the standpoint of their
underlying disease, determining the stage of ﬁbrosis,
and to determine the degree of iron loading. In the
secondary iron overload seen with other liver diseases,
iron deposition is usually mild (1þ to 2þ) and gener-
ally occurs in both perisinusoidal lining cells (Kupffer
cells) and in hepatocytes in a panlobular distribution.
59
Liver biopsy is also useful to identify the different pat-
tern of iron overload seen in patients with ferroportin
disease, wherein the iron deposition is predominantly
in reticuloendothelial cells or is in a mixed pattern of
hepatocytes and reticuloendothelial cells without a
periportal predominance.
9
Recommendations:
7. Liver biopsy is recommended for diagnosis and
prognosis in patients with phenotypic markers of
iron overload who are not C282Y homozygotes or
compound heterozygotes. (2C)
8. We recommend that in patients with non–HFE-
related HH, data on hepatic iron concentration is
useful, along with histopathologic iron staining, to
determine the degree and cellular distribution of iron
loading present. (2C)
Treatment of Hemochromatosis
Although there has never been a randomized con-
trolled trial of phlebotomy versus no phlebotomy in
treatment of HH, there is nonetheless, evidence that
initiation of phlebotomy before the development of
cirrhosis and/or diabetes will signiﬁcantly reduce the
morbidity and mortality of HH.
65,66 Therefore, early
identiﬁcation and preemptive treatment of those at risk
is generally recommended. This includes treatment of
asymptomatic individuals with homozygous HH and
markers of iron overload, as well as others with evidence
of increased levels of hepatic iron. In symptomatic
patients, treatment is also advocated to reduce progres-
sion of organ damage. Certain clinical features are likely
to be ameliorated by phlebotomy (malaise, fatigue, skin
pigmentation, insulin requirements for diabetics, and
abdominal pain), whereas other features are either less
responsive to iron removal or do not respond at all
(Table 8). These include arthropathy, hypogonadism,
and advanced cirrhosis. In some cases, hepatic ﬁbrosis
and cirrhosis show regression after phlebotomy.
67 The
life-threatening complications of established cirrhosis,
particularly HCC, continue to be a threat to survival
even after adequate phlebotomy. Therefore, patients
with cirrhosis should continue to be screened for HCC
following phlebotomy. HCC accounts for approxi-
mately 30% of HH-related deaths, whereas complica-
tions of cirrhosis account for an additional 20%.
66,68
HCC is exceptionally rare in noncirrhotic HH, which
provides an additional argument for preventive therapy
prior to the development of cirrhosis.
69
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HH (Table 9). One unit of blood contains approxi-
mately 200-250 mg iron, depending on the hemoglo-
bin concentration, and should be removed once or
twice per week as tolerated. In patients with HH who
may have total body iron stores >30 g, therapeutic
phlebotomy may take up to 2-3 years to adequately
reduce iron stores. Each phlebotomy should be pre-
ceded by measurement of the hematocrit or hemoglo-
bin so as to avoid reducing the hematocrit/hemoglobin
to <80% of the starting value. TS usually remains ele-
vated until iron stores are depleted, whereas ferritin,
which may initially ﬂuctuate, eventually begins to fall
progressively with iron mobilization and is reﬂective of
depletion of iron stores. Serum ferritin analysis should
be performed after every 10-12 phlebotomies (approxi-
mately 3 months) in the initial stages of treatment. It
can be conﬁdently assumed that excess iron stores have
been mobilized when the serum ferritin drops to
between 50 and 100 lg/L. As the target range of 50-
100 lg/L is approached, testing may be repeated more
frequently to preempt the development of overt iron
deﬁciency. It is not necessary for patients to achieve
iron deﬁciency and in fact, this should be avoided.
Phlebotomy can be stopped at the point at which iron
stores are depleted, and the patient should be assessed
for whether they require maintenance phlebotomy. For
reasons that are unclear, not all patients with HH reac-
cumulate iron and, accordingly, they may not need a
maintenance phlebotomy regimen. Therefore, the fre-
quency of maintenance phlebotomy varies among indi-
viduals, due to the variable rate of iron accumulation
in HH. Some patients (either male or female) require
maintenance phlebotomy monthly, whereas others who
reaccumulate iron at a slower rate may need only 1-2
units of blood removed per year. In the United States,
blood acquired by therapeutic phlebotomy may be
used for blood donation in some institutions, and
both the American Red Cross and the U.S. Food and
Drug Administration have deemed that the blood is
safe for transfusion.
70
The decision to treat HH with phlebotomy is
straightforward and easy to justify for patients with evi-
dence of liver disease or other end-organ manifesta-
tions. The more difﬁcult situation is the C282Y homo-
zygote patient with a ferritin level of only 800 lg/L for
example, with normal liver tests and no symptoms.
Current longitudinal data are limited; some patients
such as this will never progress to more serious prob-
lems and may not need to be treated. However, treat-
ment is easy, safe, inexpensive, and could conceivably
provide societal beneﬁt (blood donation), and thus
treatment is often initiated. Furthermore, there are no
available, reliable indicators of who will develop com-
plications. Conceivably, the rate of increase of serum
ferritin will prove in the future to be an indicator of
potential tissue and organ damage. In the absence of
results from controlled trials, we currently favor pro-
ceeding to prophylactic phlebotomy in those individu-
als who tolerate and adhere to the regimen.
In those patients with advanced disease who may
have cardiac arrhythmias or cardiomyopathy, there is
an increased risk of sudden death with rapid mobiliza-
tion of iron, most likely due to the presence of intra-
cellular iron in a relatively toxic, low-molecular-weight
chelate pool of iron. Pharmacological doses of vitamin
C accelerate mobilization of iron to a level that may
saturate circulating transferrin, resulting in an increase
in pro-oxidant and/or free radical activity.
71 Therefore,
supplemental vitamin C should be avoided by iron-
loaded patients, particularly those undergoing phlebot-
omy. No dietary adjustments are necessary, because
the amount of iron absorption that an individual
can affect with a low-iron diet is small (2-4 mg/day)
Table 9. Treatment of Hemochromatosis
Hereditary hemochromatosis
One phlebotomy (removal of 500 mL blood) weekly or biweekly
Check hematocrit/hemoglobin prior to each phlebotomy.
Allow hematocrit/hemoglobin to fall by no more than 20% of prior level
Check serum ferritin level every 10-12 phlebotomies
Stop frequent phlebotomy when serum ferritin reaches 50-100 lg/L
Continue phlebotomy at intervals to keep serum ferritin
between 50 and 100 lg/L
Avoid vitamin C supplements
Secondary iron overload due to dyserythropoiesis
Deferoxamine (Desferal) at a dose of 20-40 mg/kg body weight per day
Deferasirox (Exjade) given orally
Consider follow-up liver biopsy to ascertain adequacy of iron removal
Avoid vitamin C supplements
Table 8. Response to Phlebotomy Treatment in Patients
with HH
Reduction of tissue iron stores to normal
Improved survival if diagnosis and treatment before
development of cirrhosis and diabetes
Improved sense of well-being, energy level
Improved cardiac function
Improved control of diabetes
Reduction in abdominal pain
Reduction in skin pigmentation
Normalization of elevated liver enzymes
Reversal of hepatic ﬁbrosis (in approximately 30% of cases)
No reversal of established cirrhosis
Elimination of risk of HH-related HCC if iron removal is
achieved before development of cirrhosis
Reduction in portal hypertension in patients with cirrhosis
No (or minimal) improvement in arthropathy
No reversal of testicular atrophy
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(250 mg/week). Reports of Vibrio vulniﬁcus have been
described in patients with HH who ingest raw shell-
ﬁsh; these foods should be avoided.
72
Advanced cirrhosis is not reversed with iron re-
moval, and the development of decompensated liver
disease is an indication to consider orthotopic liver
transplantation (OLT). In the past, survival of patients
with HH who underwent liver transplantation was
lower than in those who underwent liver transplanta-
tion for other causes of liver disease.
73,74 Most post-
transplantation deaths in patients with HH occurred
in the perioperative period from either cardiac or
infection-related
72 complications.
75 These complica-
tions were probably related to inadequate removal of
excess iron stores before OLT. Currently, survival of
patients with HH after OLT is comparable to other
patients,
76 at least in part because diagnosis and treat-
ment occurs prior to OLT.
Recommendations:
9. Patients with hemochromatosis and iron overload
should undergo therapeutic phlebotomy weekly (as
tolerated). (1A) Target levels of phlebotomy should be a
ferritin level of50-100 lg/L. (1B)
10. In the absence of indicators suggestive of sig-
niﬁcant liver disease (ALT, AST elevation), C282Y
homozygotes who have an elevated ferritin (but
<1000 lg/L) should proceed to phlebotomy without
a liver biopsy. (1B)
11. Patients with end-organ damage due to iron
overload should undergo regular phlebotomy to the
same endpoints as indicated above. (1A)
12. During treatment for HH, dietary adjustments
are unnecessary. Vitamin C supplements and iron
supplements should be avoided. (1C)
13. Patients with hemochromatosis and iron over-
load should be monitored for reaccumulation of iron
and undergo maintenance phlebotomy. (1A) Target
levels of phlebotomy should be a ferritin level of 50-
100 lg/L. (1B)
14. We recommend treatment by phlebotomy of
patients with non-HFE iron overload who have an
elevated HIC. (1B)
Treatment of Secondary Iron Overload
These guidelines have primarily concentrated on the
management of HH, but it is reasonable to review the
treatment of noninherited forms of secondary iron
overload. The causes of secondary iron overload are
listed in Table 3.
Phlebotomy is useful in certain forms of secondary
iron overload (Table 8). Phlebotomy is clearly indi-
cated in patients with PCT, and results in a reduction
in skin manifestations. Total iron stores rarely exceeds
4-5 g. Secondary iron overload is sometimes seen in
association with chronic hepatitis C, NAFLD, and
ALD.
77 There is no published evidence that phlebot-
omy is of beneﬁt in ALD. In chronic hepatitis C, it
has been shown that phlebotomy therapy reduces ele-
vated ALT levels and achieves a marginal improvement
in histopathology, but has no effect on virologic clear-
ance.
78 Currently, phlebotomy is not recommended
for mild secondary iron overload (HIC < 2500 lg/g
dry weight) in chronic hepatitis C. In NAFLD, studies
have shown a beneﬁt of therapeutic phlebotomy with
improvement in parameters of insulin resistance and
reduction in elevated ALT levels.
79,80 Large-scale stud-
ies in patients with NAFLD have been proposed.
In secondary iron overload associated with ineffec-
tive erythropoiesis, iron chelation therapy with paren-
teral deferoxamine is the treatment of choice. Numer-
ous studies have documented the efﬁcacy of
deferoxamine in preventing the complications of iron
overload in b-thalassemia.
81 Recently, deferasirox
(Exjade), an orally administered iron-chelating drug,
has been approved in the United States for treatment
of secondary iron overload due to ineffective erythro-
poiesis. Studies are ongoing regarding its potential use
in HH. However, recent concerns about complications
have tempered enthusiasm for this drug in HH.
82 De-
feroxamine is usually administered by continuous sub-
cutaneous infusion using a battery-operated infusion
pump at a dose of 40 mg/kg/day for 8-12 hours
nightly for 5-7 nights weekly. A total dose of approxi-
mately 2 g per 24 hours usually achieves maximal uri-
nary iron excretion. Chelation therapy to reduce HIC
< 15,000 lg/g dry weight signiﬁcantly reduces the
risk of clinical disease.
83 The application of deferoxa-
mine therapy is limited by cost, the need for a paren-
teral route of therapy, discomfort, inconvenience, and
neurotoxcity. Monitoring iron reduction in patients
with secondary iron overload is challenging. In con-
trast to HH, where serum ferritin reliably reﬂects iron
burden during therapy, ferritin levels can be misleading
in secondary iron overload. In some patients, it may
be necessary to repeat liver biopsy to assess the pro-
gress of therapy and ensure adequate chelation.
84
Monitoring 24-hour urinary iron excretion is some-
times helpful. By detecting magnetic susceptibility, a
superconducting quantum interference device
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range, but this is a research technique that is available
only in a few centers worldwide.
85 The recent develop-
ment of certain magnetic resonance imaging programs
has shown promise in providing a noninvasive method
to evaluate HIC.
86,87 In patients with secondary iron
overload, HIC provides an accurate quantitative means
for monitoring iron balance.
88
Recommendations:
15. Iron chelation with either deferoxamine mesy-
late or deferasirox is recommended in iron over-
loaded patients with dyserythropoietic syndromes or
chronic hemolytic anemia. (1A)
Surveillance for Hepatocellular Cancer
In patients with HH who present with cirrhosis, the
recent AASLD guidelines for HCC surveillance should
be followed.
89 These recommendations should be
extended to patients with HH who have cirrhosis,
whether they have had phlebotomy to restore normal
iron levels. The relative risk for HCC is approximately
20, with an annual incidence of 3%-4%.
89 Patients
with HH with advanced ﬁbrosis or cirrhosis should be
screened regularly for HCC as per AASLD guidelines.
General Population Screening
When considering the evidence required to deter-
mine whether general population screening should be
performed for the C282Y mutation, a key factor is the
clinical penetrance of C282Y homozygosity. Approxi-
mately 30% of C282Y homozygotes do not have phe-
notypic expression of excess iron stores in cross-sec-
tional studies (Table 2). Because of this, from a public
policy perspective, general population screening for
HH is not indicated. In a large Norwegian study,
65,238 subjects were screened using TS, and when it
was elevated on two determinations, cases were con-
ﬁrmed by genetic testing and/or liver biopsy.
11 In 147
subjects, liver biopsies were performed and only four
men and none of the women had cirrhosis (2.7%
prevalence of cirrhosis). An Australian population
study of 3011 individuals revealed 16 C282Y homozy-
gotes. Of these 16, liver biopsy was performed in 11
cases with serum ferritin >300 lg/L, of whom three
were identiﬁed with advanced ﬁbrosis and one with
cirrhosis who had associated ALD (6.3% prevalence of
cirrhosis).
90 Other prospective population studies have
reached similar conclusions that the clinical penetrance
of C282Y homozygosity is quite low.
10,12 This discrep-
ancy between the morbidity seen in referred patients
and the lack of morbidity in screened patients is not
unique to HH.
Economic models that have included genetic testing
have suggested that population screening for HH
would be effective if only 20% of patients developed
life-threatening complications.
91,92 The natural history
of untreated HH has been illustrated in the Copenha-
gen Heart Study, where patients were followed for 25
years with serial ferritin testing without an awareness
that they were C282Y homozygotes.
93 Many patients
did not demonstrate progression of iron overload as
measured by serum ferritin, and the costs of investigat-
ing false positive iron tests in a screening program
were considered signiﬁcant. This has led some to con-
sider that a genetic test should be done ﬁrst, followed
by measurement of serum ferritin. There have been
concerns expressed about the adverse effects of genetic
testing such as genetic discrimination; however, several
studies have demonstrated that this is rarely a valid
concern.
94 Nonetheless, widespread population screen-
ing for HH is not recommended, whereas more selec-
tive screening in high-risk populations needs further
study.
5,95
Recommendations:
16. Average risk population screening for HH is
not recommended.
93 (1B)
Screening for Non–HFE-related HH
The term ‘‘non–HFE-related HH’’ refers to several
genetically distinct forms of inherited iron overload
affecting individuals without HFE mutations.
17 Several
of the genes involved are hemojuvelin (HJV), ferropor-
tin (SLC40A1), transferrin receptor 2 (TFR2), and
hepcidin (HAMP). The non-HFE forms of inherited
iron overload are rare, accounting for <5% of cases
encountered, and genetic testing is largely unavailable
except in research laboratories.
Screening for non–HFE-related HH is not
recommended.
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